Format

Send to

Choose Destination
J Exerc Rehabil. 2014 Apr 30;10(2):54-9. doi: 10.12965/jer.140100. eCollection 2014 Apr.

Role of adiponectin in metabolic and cardiovascular disease.

Author information

1
Dalton Cardiovascular Research Center, University of Missouri-Columbia, MO, USA.
2
Department of Kinesiology, Inha University, Incheon, Korea.

Abstract

Under disease conditions including obesity (insulin resistance) and diabetes, dysregulation of adipokines such as tumor necrosis factor (TNF)-α, leptin, resistin, and adiponectin contribute to the development of metabolic and cardiovascular disease. Unlike other adipokines, adiponectin has been shown to be a therapeutic target for metabolic syndrome and cardiovascular disease. Circulating levels of adiponectin are markedly reduced in obese, diabetic, hypertensive, and coronary artery disease patients as well as experimental animal models of insulin resistance and diabetes. Recently, the small molecule adiponectin receptors (AdipoRs) agonist was discovered and suggested that the agonist is a novel therapeutic target for the treatment of type 2 diabetes linked to obesity in an experimental mouse model. This review will focus on signaling pathways involved in adiponectin and its receptors and the role of adiponectin in metabolic and cardiovascular disease including insulin resistance, cardiomyopathy, and cardiovascular dysfunction.

KEYWORDS:

AMPK; AdipoRON; Adiponectin receptors; PPARα

Supplemental Content

Full text links

Icon for Korean Society of Exercise Rehabilitation Icon for PubMed Central
Loading ...
Support Center